The Journal of urology
-
The Journal of urology · Oct 2013
National trends in augmentation cystoplasty in the 2000s and factors associated with patient outcomes.
Augmentation cystoplasty is a major surgery performed by pediatric urologists. We evaluated national estimates of children undergoing augmentation cystoplasty in the United States for trends during the 2000s, and analyzed patient and hospital factors associated with outcomes. ⋯ The estimated number of augmentation cystoplasties performed in children in the United States decreased by 25% in the 2000s, and mean length of stay decreased by 1 day. The cause of the decrease is multifactorial but could represent changing practice patterns in the United States. Of the patients 30% had a potential complication during hospitalization after augmentation cystoplasty. Older age and bladder exstrophy-epispadias complex diagnosis were associated with greater length of stay and increased odds of having any complication.
-
The Journal of urology · Oct 2013
Comment LetterRe: Robot-assisted versus open radical prostatectomy: the differential effect of regionalization, procedure volume and operative approach: J. D. Sammon, P. I. Karakiewicz, M. Sun, S. Sukumar, P. Ravi, K. R. Ghani, M. Bianchi, J. O. Peabody, S. F. Shariat, P. Perrotte, J. C. Hu, M. Menon and Q. D. Trinh J Urol 2013; 189: 1289-1294.
-
The Journal of urology · Sep 2013
Randomized Controlled Trial Multicenter Study Comparative StudyThe impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Bacillus Calmette-Guérin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer. Although bacillus Calmette-Guérin is perceived as less tolerable than intravesical chemotherapy, to our knowledge no comparative studies have addressed quality of life issues. We compared the quality of life of patients with nonmuscle invasive bladder cancer who received adjuvant intravesical gemcitabine or 1/3 dose bacillus Calmette-Guérin. ⋯ While a higher rate of side effects, albeit mild to moderate, was detected with 1/3 dose bacillus Calmette-Guérin compared to gemcitabine, our study failed to show significant differences between the 2 drugs in terms of quality of life.